Tumor-specific promoters were a recurring strategy, as evidenced by a study by Reinblatt et al. [98], which engineered CEA-secreting CRC cells to enhance HSV-1 (G207) replication and cytotoxicity, explicitly targeting the tumor. The gene discussed is CEACAM5; the disease is neoplasm.